at Investor's Business Daily (Jan 6, 2015)
Raptor Pharmaceutical (RPTP +16%) surges to a new 52-week high today, after the company reported late yesterday that the FDA's Office of Orphan Product Development has granted seven-year orphan drug exclusivity for Procysbi delayed-release capsules for the management of nephropathic cystinosis. The exclusivity period began on the date of the drug's initial FDA approval, April 30.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Investor's Business Daily (Jan 5, 2015)
at Nasdaq.com (Dec 29, 2014)
at CNBC.com (Mar 13, 2014)
at CNBC.com (Feb 20, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs